Single-Cell Protein

Protein derived from microbial biomass prepared for feed or food applications.

LUX TAKE:

Today, single-cell protein (SCP) is at the startup level and faces high investment costs. However, the use of microbes to produce proteins offers advantages over conventional methods, including a short generation time and high-volume production. Accordingly, SCP will play a major part in the future of protein production once inputs are accessible and affordable. Companies with feedstock supplies, ...

Lux Take last updated on July 08, 2020
Data last updated on January 21, 2021

What's New

Lux Research analysts and the Lux Intelligence Engine have added the following recent single-cell protein developments.

News Commentaries

Air Protein's $32 million Series A signals funding momentum in CO₂-based protein for human food (January 8, 2021)

Nature's Fynd raises additional $45 million for its fungi-based protein, adds industry veterans to team (December 10, 2020)

New Lux Content

Avecom (October 9, 2020)

Calidris Bio (September 30, 2020)

New Patents

Computing...

New Investment Rounds

Computing...

Related companies	LanzaTech, Kiverdi, Calysta, Unibio, Arbiom, White Dog Labs, KnipBio, String Bio, NovoNutrients, Solar Foods, Nature's Fynd, Menon Renewable Products, BioKind, Deep Branch Biotechnology, iCell Sustainable Nutrition, Air Protein, EniferBio, Utilization of Carbon Dioxide Institute Co.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978